Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LCK | P06239 | 11/20 | 0.50 |
| ▸ | ATR | Q13535 | 1/20 | 0.43 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | CA12 | O43570 | 1/20 | 0.41 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 1/20 | 0.41 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.41 |
| ▸ | S1PR2 | O95136 | 1/20 | 0.40 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.40 |
| ▸ | PTPRB | P23467 | 1/20 | 0.40 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20865564 | 0.84 | LCK (0.50) | LCKATRCA12CA1CA9 | |
| SCHEMBL3131919 | 0.84 | LCK (0.60) | LCKCA12CA1CA9 | |
| SCHEMBL17528556 | 0.83 | LCK (0.49) | LCKATRCA12CA1CA9 | |
| SCHEMBL25243093 | 0.81 | LCK (0.62) | LCKHPGDCA12CA1CA9 | |
| SCHEMBL30830461 | 0.81 | LCK (0.48) | LCKATRCA12CA1CA9 | |
| SCHEMBL5840611 | 0.80 | LCK (0.41) | LCKHPGDCYP3A4CA12CA1 | |
| SCHEMBL30830459 | 0.80 | LCK (0.47) | LCKATRHPGDCA12CA1 | |
| SCHEMBL3606323 | 0.80 | ALDH1A1 (0.42) | LCKATRCA12CA1CA9 | |
| SCHEMBL2157110 | 0.80 | RAB9A (0.53) | CA12CA1CA9 | |
| SCHEMBL4723839 | 0.79 | KMT2A (0.54) | CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11111252-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2021-09-07 | — | — | US | disclosed |
| US-11001595-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2021-05-11 | — | — | US | disclosed |
| US-20200369680-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-11-26 | — | — | US | disclosed |
| US-20200369681-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT | 2020-11-26 | — | — | US | disclosed |
| US-10774090-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2020-09-15 | — | — | US | disclosed |
| US-20190233432-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2019-08-01 | — | — | US | disclosed |
| US-10233194-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | Duquesne Unversity of the Holy Spirit (US) | 2019-03-19 | — | — | US | disclosed |
| US-20170253612-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-09-07 | — | — | US | disclosed |
| US-20170253612-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2017-09-07 | — | — | US | disclosed |
| US-9688690-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2017-06-27 | — | — | US | disclosed |
| US-9688690-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DUQUESNE UNIVERSITY OF THE HOLY GHOST (US) | 2017-06-27 | — | — | US | disclosed |
| WO-2016022890-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | DUQUESNE UNIVERSITY OF THE HOLY SPIRIT (US) | 2016-02-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200369680-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | DPYD, HPRT1, TPMT | LCK 378/4885ATR 401/4885HPGD 142/4885 |
| US-10233194-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DPYD, HPRT1, TPMT | LCK 335/4885ATR 442/4885HPGD 230/4885 |
| US-20200369681-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | DPYD, TYMP, TPMT | LCK 302/4885ATR 919/4885HPGD 164/4885 |
| US-20190233432-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | DPYD, HPRT1, TPMT | LCK 358/4885ATR 377/4885HPGD 150/4885 |
| US-20170253612-A1 | PYRIMIDINE COMPOUNDS AND PYRIMIDO INDOLE COMPOUNDS AND METHODS OF USE | DPYD, HPRT1, TPMT | LCK 335/4885ATR 442/4885HPGD 230/4885 |
| US-10774090-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DPYD, HPRT1, TPMT | LCK 358/4885ATR 377/4885HPGD 150/4885 |
| US-11111252-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DPYD, TYMP, TPMT | LCK 302/4885ATR 919/4885HPGD 164/4885 |
| US-11001595-B2 | Pyrimidine compounds and pyrimido indole compounds and methods of use | DPYD, HPRT1, TPMT | LCK 378/4885ATR 401/4885HPGD 142/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.